trial

Cross-Sectional Iloperidone IVGTT

NCTId NCT01686815

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase — · Completed

Enrollment 37 (actual)

Sponsored by Massachusetts General Hospital

Primary completion 2016-05

Synthesized from structured facts only — each point cited above.

Design & status

Phase

—

Status

Completed

Enrollment

37 (actual)

Study type

Observational

Allocation

—

Model

—

Masking

—

Start

2012-10

Primary completion

2016-05

Eligibility

ALL · 18 Years · 65 Years

Interventions & indications

Drugs

—

Indications

Insulin Resistance Serious Mental Illness Insulin Resistance Metabolic Syndrome Schizophrenia Schizophrenia Metabolic Syndrome Glucose Metabolism

Investigators

Maurizio Fava, MDPrincipal Investigator

Sites

1 total

Boston, United States

Facts & assertions

4 sourced

Enrollment

Phase

Primary Completion Date

2016-05

Status

COMPLETED

relationships

The graph out of here

lead_sponsor

Massachusetts General Hospital

company

collaborator

Novartis Pharmaceuticals

company

indication

Insulin Resistance

indication

Serious Mental Illness

indication

Insulin Resistance

indication

investigator

Maurizio Fava, MD

person